Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Other Accumulated Expenses (2016 - 2025)

CV Sciences' Other Accumulated Expenses history spans 10 years, with the latest figure at $1.1 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 23.96% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 23.96% decrease, with the full-year FY2025 number at $1.1 million, down 23.96% from a year prior.
  • Other Accumulated Expenses hit $1.1 million in Q4 2025 for CV Sciences, down from $1.5 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for CVSI hit a ceiling of $1.6 million in Q2 2025 and a floor of $1.1 million in Q4 2025.
  • Historically, Other Accumulated Expenses has averaged $1.4 million across 4 years, with a median of $1.5 million in 2024.
  • The widest YoY moves for Other Accumulated Expenses: up 6.85% in 2025, down 23.96% in 2025.
  • Tracing CVSI's Other Accumulated Expenses over 4 years: stood at $1.5 million in 2022, then fell by 2.39% to $1.5 million in 2023, then fell by 5.89% to $1.4 million in 2024, then decreased by 23.96% to $1.1 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for CVSI at $1.1 million in Q4 2025, $1.5 million in Q3 2025, and $1.6 million in Q2 2025.